Attralus

Attralus, Inc., led by CEO Spencer Guthrie, is a clinical-stage biopharmaceutical company focused on developing transformative therapies to improve the lives of patients with systemic amyloidosis. The company’s proprietary Pan-Amyloid Removal (PAR) therapy is designed to directly bind to and remove toxic amyloid proteins from organs and tissues. By targeting the universal pathogenic pathology of systemic amyloidosis, PAR therapy has the potential to treat and reverse disease in all types and stages of systemic amyloidosis patients.